[go: up one dir, main page]

PE20221630A1 - Derivado de amino arilo novedoso util como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo - Google Patents

Derivado de amino arilo novedoso util como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo

Info

Publication number
PE20221630A1
PE20221630A1 PE2022001028A PE2022001028A PE20221630A1 PE 20221630 A1 PE20221630 A1 PE 20221630A1 PE 2022001028 A PE2022001028 A PE 2022001028A PE 2022001028 A PE2022001028 A PE 2022001028A PE 20221630 A1 PE20221630 A1 PE 20221630A1
Authority
PE
Peru
Prior art keywords
inhibitor
diacyl glycerol
amino aryl
novel amino
derivative useful
Prior art date
Application number
PE2022001028A
Other languages
English (en)
Inventor
Seung Hyun Yoon
Hyun Woo Joo
Bo Kyung Seo
Eun Jin Lee
Jin Young Jung
Su Young Yoon
Woo Young Cho
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of PE20221630A1 publication Critical patent/PE20221630A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE AMINO ARILO DE FORMULA (1) DONDE R1, R2, R3, A, B, D Y E SON TAL COMO SE DESCRIBEN EN EL PRESENTE DOCUMENTO. SON COMPUESTOS PREFERIDOS: ACIDO (R)-2-((6-(3-(2-ETOXIFENOXI)PIPERIDIN-1-IL)-PIRAZIN-2-IL)AMINO)TIAZOL-5-CARBOXILICO; (R)-N-(6-(3-(2-ETOXIFENOXI)PIPERIDIN-1-IL)PIRAZIN-2-IL)-4,5-DIMETILTIAZOL-2-AMINA; (R)-N-(6-(3-(2-ETOXIFENOXI)PIPERIDIN-1-IL)PIRAZIN-2-IL)-4-FENILTIAZOL-2-AMINA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA DIACILGLICEROL ACILTRANSFERASA 2 (DGAT2) SIENDO UTILES EN EL TRATAMIENTO DE HIGADO GRASO, ESTEATOHEPATITIS NO ALCOHOLICA (NASH), DIABETES, OBESIDAD.
PE2022001028A 2019-12-23 2020-12-22 Derivado de amino arilo novedoso util como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo PE20221630A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190173487 2019-12-23
PCT/KR2020/018929 WO2021133035A1 (ko) 2019-12-23 2020-12-22 디아실글리세롤 아실트랜스퍼라제 2 억제제로서 유용한 신규 아미노 아릴 유도체 및 이의 용도

Publications (1)

Publication Number Publication Date
PE20221630A1 true PE20221630A1 (es) 2022-10-19

Family

ID=76575608

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001028A PE20221630A1 (es) 2019-12-23 2020-12-22 Derivado de amino arilo novedoso util como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo

Country Status (20)

Country Link
US (1) US20230078941A1 (es)
EP (1) EP4071147B1 (es)
JP (1) JP7438602B2 (es)
KR (1) KR102528255B1 (es)
CN (1) CN114846013B (es)
AU (1) AU2020414202B2 (es)
BR (1) BR112022012368A2 (es)
CL (1) CL2022001658A1 (es)
CO (1) CO2022010011A2 (es)
ES (1) ES3023238T3 (es)
IL (1) IL294139B2 (es)
JO (1) JOP20220158A1 (es)
MX (1) MX2022007255A (es)
MY (1) MY201006A (es)
PE (1) PE20221630A1 (es)
PH (1) PH12022551271A1 (es)
TW (1) TWI762100B (es)
UA (1) UA129065C2 (es)
WO (1) WO2021133035A1 (es)
ZA (1) ZA202207793B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022007810A (es) * 2019-12-23 2022-07-19 Lg Chemical Ltd Derivado de amida novedoso util como inhibidor de diacilglicerol aciltransferasa 2, y uso del mismo.
IL321166A (en) 2022-12-02 2025-07-01 Merck Sharp & Dohme Llc Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316844A (zh) * 2005-11-28 2008-12-03 霍夫曼-拉罗奇有限公司 二酰甘油酰基转移酶(dgat)抑制剂
WO2010022055A2 (en) * 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
AU2011218167B2 (en) * 2010-02-17 2014-07-10 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
WO2013068328A1 (en) * 2011-11-07 2013-05-16 Intervet International B.V. Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
SI3119757T1 (en) * 2014-03-17 2018-08-31 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
AR109179A1 (es) * 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2

Also Published As

Publication number Publication date
IL294139A (en) 2022-08-01
WO2021133035A1 (ko) 2021-07-01
CO2022010011A2 (es) 2022-08-30
CN114846013A (zh) 2022-08-02
ZA202207793B (en) 2023-04-26
MX2022007255A (es) 2022-07-13
KR102528255B1 (ko) 2023-05-03
UA129065C2 (uk) 2025-01-01
CA3160366A1 (en) 2021-07-01
TW202130632A (zh) 2021-08-16
TWI762100B (zh) 2022-04-21
CN114846013B (zh) 2024-12-20
IL294139B1 (en) 2025-07-01
ES3023238T3 (en) 2025-05-30
JP2023508972A (ja) 2023-03-06
NZ788624A (en) 2025-08-29
AU2020414202A1 (en) 2022-07-14
IL294139B2 (en) 2025-11-01
AU2020414202B2 (en) 2024-01-04
US20230078941A1 (en) 2023-03-16
EP4071147A4 (en) 2023-01-18
EP4071147B1 (en) 2025-03-26
JOP20220158A1 (ar) 2023-01-30
MY201006A (en) 2024-01-30
PH12022551271A1 (en) 2023-11-29
JP7438602B2 (ja) 2024-02-27
CL2022001658A1 (es) 2023-02-10
KR20210081286A (ko) 2021-07-01
BR112022012368A2 (pt) 2022-08-30
EP4071147A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PE20140626A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20191755A1 (es) Derivados de pirazol como inhibidores de malt 1
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
PE20191020A1 (es) Compuestos quimicos
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
PE20161396A1 (es) Compuesto heterociclico
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
PE20161371A1 (es) Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
PE20142098A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
PE20090641A1 (es) Amidas heterociclicas
PE20142099A1 (es) Derivados de sulfonamida
HN2009001160A (es) Inhibidores de transcriptasa inversa no nucleosidicos
PE20091816A1 (es) Inhibidores de bace
PE20091201A1 (es) AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)
PE20081354A1 (es) Compuestos de azaindolilo como inhibidores de mek
PE20211472A1 (es) Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
AR047085A1 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalina-2-il-amino)benzamida y compuestos relacionados como inhibidores de glucogeno fosforilasa para el tratamiento de diabetes y obesidad
PE20190106A1 (es) Inhibidores del potenciador del homologo zeste 2
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
PE20161369A1 (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona sustituidos con tetrazolona